[ad_1]
Paramus, New Jersey, March 25, 2024 (GLOBE NEWSWIRE) — Starton Therapeutics Inc. (“Starton” or the “Company”), A clinical-stage biotech company focused on changing the standard of care through proprietary sustained delivery technology, today announced that Starton Therapeutics Chairman and CEO Pedro Lichtinger will attend and host one-on-one meetings at MedInvest Biotech & Pharma Investor and 23rd Needham Annual Virtual Healthcare Conference. Event details are as follows:
MedInvest Biotech and Pharmaceutical Investor Conference
Lecture date: Thursday, April 4, 2024
Time: 11:10 a.m. Eastern Time
For one-on-one meetings and more information about conferences, visit Medical investment.
23rd Annual Needham Virtual Healthcare Conference
Demo date: Monday, April 8, 2024
Time: 9:30 AM Eastern Time
For one-on-one meetings and more information about meetings, please contact your bank sales representative.
About the Staton Therapy
Starton Therapeutics is a clinical-stage biotechnology platform company committed to changing the standard of care through proprietary continuous delivery technology, enabling cancer patients to receive continuous treatment to live better and longer. Starton’s proprietary transdermal technology is designed to improve the efficacy of approved drugs, make them more tolerable and expand their potential uses.To learn more, please visit www.startontx.com.
forward-looking statements
This press release contains statements that constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the company’s control. The Company undertakes no obligation to update any revisions or changes to these statements after the date of this release, except as required by law.
Investor Relations:
investors@startontx.com
[ad_2]
Source link